
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd is positioned for significant growth in the diagnostics market, particularly through the introduction of a feline assay that could potentially double its total addressable market for companion animal testing, capitalizing on increasing awareness of feline oncology. The company's expanded scientific narrative supports a combined annualized total addressable market of approximately $36 billion for multi-cancer early detection and minimal residual disease, bolstering its strategic partnerships and commercialization efforts. Furthermore, the development and market entry of the Nu.Q Vet Feline Test and the establishment of additional laboratory partnerships enhance Volition's geographic reach and establish new recurring revenue streams, reinforcing a positive long-term outlook for the company.
Bears say
VolitionRX Ltd has faced challenges in achieving significant revenue growth, with recent financial reports indicating inconsistent performance and lack of widespread market adoption of its blood tests. The company's dependence on the development of its Nucleosomics platform has resulted in substantial research and development expenses, contributing to ongoing operating losses and raising concerns about long-term sustainability. Additionally, competitive pressures within the diagnostics space, coupled with potential regulatory hurdles, have further exacerbated uncertainty regarding VolitionRX's future financial performance.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares